3.74
Molecular Partners Ag Adr stock is traded at $3.74, with a volume of 133.
It is up +7.47% in the last 24 hours and up +3.60% over the past month.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
See More
Previous Close:
$3.48
Open:
$3.665
24h Volume:
133
Relative Volume:
0.05
Market Cap:
$147.97M
Revenue:
$7.80M
Net Income/Loss:
$-69.02M
P/E Ratio:
-1.7466
EPS:
-2.1413
Net Cash Flow:
$-66.61M
1W Performance:
+1.08%
1M Performance:
+3.60%
6M Performance:
-24.75%
1Y Performance:
-38.18%
Molecular Partners Ag Adr Stock (MOLN) Company Profile
Name
Molecular Partners Ag Adr
Sector
Industry
Phone
-
Address
-
Compare MOLN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
MOLN
Molecular Partners Ag Adr
|
3.665 | 145.29M | 7.80M | -69.02M | -66.61M | -2.1413 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
382.52 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.70 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
428.88 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
670.61 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.02 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Molecular Partners Ag Adr Stock (MOLN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-30-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Aug-29-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
May-25-22 | Upgrade | Credit Suisse | Underperform → Neutral |
Apr-27-22 | Downgrade | Credit Suisse | Neutral → Underperform |
Jul-13-21 | Initiated | Cowen | Outperform |
Jul-12-21 | Resumed | SVB Leerink | Outperform |
View All
Molecular Partners Ag Adr Stock (MOLN) Latest News
Molecular Partners (NASDAQ:MOLN) Stock Price Down 3.4% – Should You Sell? - Defense World
Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025 - GlobeNewswire Inc.
Walmart, Deere, Applied Materials set to report earnings Thursday By Investing.com - Investing.com Nigeria
Walmart, Deere, Applied Materials set to report earnings Thursday - Investing.com
Ziff Davis Inc (NASDAQ:ZD) Shares Jumped 1.54% In A Week. Can It Continue Rising? - Marketing Sentinel
Molecular Partners' AACR 2025 Breakthroughs: Radio-DARPins and Smart T Cell Engagers Ignite Oncology Potential - AInvest
Can Contango ORE, Inc. (CTGO) Climb 163.28% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
Here's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom Fisher - Yahoo Finance
Musk's DOGE Exit Rumors & Weak Q1 Deliveries: How to Play Tesla Now - Yahoo Finance
Why Tractor Supply (TSCO) is a Top Momentum Stock for the Long-Term - Yahoo Finance
TD Cowen maintains Buy on Molecular Partners, target CHF15 - Investing.com India
Molecular Partners reports 2024 annual results - Investing.com India
Wall Street Analysts Think Molecular Partners AG Sponsored ADR (MOLN) Could Surge 80.72%: Read This Before Placing a Bet - Yahoo Finance
Molecular Partners: Sellers Have Disappeared, Enterprise Value Below Zero (NASDAQ:MOLN) - Seeking Alpha
US stock market gainers for the last week of April 2022 - Nairametrics
Novartis to push forward with covid drug after positive results - Luxembourg Times
Wall Street Analysts See a 96% Upside in Molecular Partners AG Sponsored ADR (MOLN): Can the Stock Really Move This High? - Yahoo Finance
Citi Appointed as Depositary Bank for Molecular Partners AG’s ADR Programme - Business Wire
Molecular Partners Ag Adr Stock (MOLN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):